Genetic and prognostic differences of non-small cell lung cancer between elderly patients and younger counterparts

Aging and Disease

Volumn 3, Issue 6, 2012, Pages 438-443

  Suda, Kenichi ^a   Tomizawa, Kenji ^b   Mizuuchi, Hiroshi ^a,c   Ito, Simon ^b   Kitahara, Hirokazu ^a   Shimamatsu, Shinichiro ^a   Kohno, Mikihiro ^a   Yoshida, Tsukihisa ^a   Okamoto, Tatsuro ^a   Maehara, Yoshihiko ^a   Yatabe, Yasushi ^b   Mitsudomi, Tetsuya ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anaplastic lymphoma kinase translocation; Epidermal growth factor receptor gene mutation; Oncogenic driver mutation; Prognostic factor; Recurrence free survival

Indexed keywords

EID: 84876839881     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a cancer journal for clinicians, 61:212-236.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T (2012). Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jap J Clin Oncol, 42:139-147.
3. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 11:121-128.
4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362:2380-2388.
5. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. (2011). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363:1693-1703.
6. Mery CM, Pappas AN, Bueno R, Colson YL, Linden P, Sugarbaker DJ, et al. (2005). Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest, 128:237-245.
7. Ryu JS, Choi CM, Yang SC, Song SY, Jeon YJ, Jang TW, et al. (2012). Prognostic effect of age on survival of patients with stage I adenocarcinoma of the lung. Tumori, 98:99-104.
8. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. (2008). Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol, 26:54-59.
9. Ng R, de Boer R, Green MD. (2005). Undertreatment of elderly patients with non-small-cell lung cancer. Clin Lung Cancer, 7:168-174.
10. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T (2009). Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol, 4:22-29.
11. Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, et al. (2012). Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer, in press.
12. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, et al. (2009). EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol, 22:508-515.
13. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, et al. (2012). Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer, 76:403-409.
14. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. (2009). First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol, 27:1394-1400.
15. Langer CJ (2009). The lazarus response in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol, 27:1350-1354.
16. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, et al. (2012). Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res, 18:1947-1953.
17. Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, et al. (2005). Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer, 47:385-394.
18. Quoix E, Westeel V, Zalcman G, Milleron B (2011). Chemotherapy in elderly patients with advanced non-small cell lung cacer. Lung Cancer, 74:364-368.